Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Intra-anal Oxymetazoline in Healthy Volunteers
NCT03529487Phase 1Unknown
- Sponsor
- RDD Pharma
- Start
- Aug 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Mucinex Full Force Nasal Spray in fecal incontinence (FI) (3 arms), sponsored by RDD Pharma. Primary endpoints: Maximum Plasma Concentration at 11 days, Time to Maximum Plasma Concentration at 11 days and 2 more. Status: unknown.
02
Drugs
Mucinex Full Force Nasal Spray
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT03529487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529487.